Novartis Sues Crystal, Adding Patents to Their Entresto Dispute

Sept. 27, 2021, 3:33 PM

Novartis said Crystal Pharmaceutical’s proposed generic version of Entresto infringes two patents related to the blockbuster treatment for heart failure, expanding the companies’ legal fight.

  • Novartis is seeking court order blocking copies until patents have expired and cash compensation if copies are made before then, according to complaint filed Friday in federal court in Wilmington, Delaware
  • Patents expire in August 2033: supplemental filing
  • Novartis last week filed suit in Delaware against Alkem, Aurobindo, Dr. Reddy’s, Hetero, Laurus, Macleods and Torrent over patent issued last month related to Entresto
  • Novartis in 2019 sued those companies and ...

To read the full article log in.

Learn more about a Bloomberg Law subscription